RIC8B

Across TCGA pan-cancer cohorts, RIC8B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RIC8B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RIC8B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RIC8B is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where RIC8B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIC8B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.232	<.001	6	view →
LUAD	All	All	−0.210	<.001	5	view →
HNSC	All	III,IV	+0.222	.045	2	view →
PDAC	Female	III,IV	+0.467	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RIC8B–CCRCC

Open the CCRCC breakdown →